JP2018532804A5 - - Google Patents

Download PDF

Info

Publication number
JP2018532804A5
JP2018532804A5 JP2018543040A JP2018543040A JP2018532804A5 JP 2018532804 A5 JP2018532804 A5 JP 2018532804A5 JP 2018543040 A JP2018543040 A JP 2018543040A JP 2018543040 A JP2018543040 A JP 2018543040A JP 2018532804 A5 JP2018532804 A5 JP 2018532804A5
Authority
JP
Japan
Prior art keywords
composition
subject
uveitis
antibody
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018543040A
Other languages
English (en)
Japanese (ja)
Other versions
JP7272794B2 (ja
JP2018532804A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/060344 external-priority patent/WO2017079443A1/en
Publication of JP2018532804A publication Critical patent/JP2018532804A/ja
Publication of JP2018532804A5 publication Critical patent/JP2018532804A5/ja
Priority to JP2021147378A priority Critical patent/JP2021193120A/ja
Priority to JP2023021270A priority patent/JP7581399B2/ja
Application granted granted Critical
Publication of JP7272794B2 publication Critical patent/JP7272794B2/ja
Priority to JP2024189424A priority patent/JP2025020227A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018543040A 2015-11-03 2016-11-03 ブドウ膜炎および黄斑浮腫の処置のためのil6r抗体を含む組成物およびそれを使用する方法 Active JP7272794B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021147378A JP2021193120A (ja) 2015-11-03 2021-09-10 ブドウ膜炎および黄斑浮腫の処置のためのil6r抗体を含む組成物およびそれを使用する方法
JP2023021270A JP7581399B2 (ja) 2015-11-03 2023-02-15 ブドウ膜炎および黄斑浮腫の処置のためのil6r抗体を含む組成物およびそれを使用する方法
JP2024189424A JP2025020227A (ja) 2015-11-03 2024-10-29 ブドウ膜炎および黄斑浮腫の処置のためのil6r抗体を含む組成物およびそれを使用する方法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562250269P 2015-11-03 2015-11-03
US62/250,269 2015-11-03
EP16306166 2016-09-14
EP16306166.6 2016-09-14
US201662408391P 2016-10-14 2016-10-14
US62/408,391 2016-10-14
PCT/US2016/060344 WO2017079443A1 (en) 2015-11-03 2016-11-03 Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021147378A Division JP2021193120A (ja) 2015-11-03 2021-09-10 ブドウ膜炎および黄斑浮腫の処置のためのil6r抗体を含む組成物およびそれを使用する方法

Publications (3)

Publication Number Publication Date
JP2018532804A JP2018532804A (ja) 2018-11-08
JP2018532804A5 true JP2018532804A5 (https=) 2019-12-05
JP7272794B2 JP7272794B2 (ja) 2023-05-12

Family

ID=57018106

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018543040A Active JP7272794B2 (ja) 2015-11-03 2016-11-03 ブドウ膜炎および黄斑浮腫の処置のためのil6r抗体を含む組成物およびそれを使用する方法
JP2021147378A Pending JP2021193120A (ja) 2015-11-03 2021-09-10 ブドウ膜炎および黄斑浮腫の処置のためのil6r抗体を含む組成物およびそれを使用する方法
JP2023021270A Active JP7581399B2 (ja) 2015-11-03 2023-02-15 ブドウ膜炎および黄斑浮腫の処置のためのil6r抗体を含む組成物およびそれを使用する方法
JP2024189424A Pending JP2025020227A (ja) 2015-11-03 2024-10-29 ブドウ膜炎および黄斑浮腫の処置のためのil6r抗体を含む組成物およびそれを使用する方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021147378A Pending JP2021193120A (ja) 2015-11-03 2021-09-10 ブドウ膜炎および黄斑浮腫の処置のためのil6r抗体を含む組成物およびそれを使用する方法
JP2023021270A Active JP7581399B2 (ja) 2015-11-03 2023-02-15 ブドウ膜炎および黄斑浮腫の処置のためのil6r抗体を含む組成物およびそれを使用する方法
JP2024189424A Pending JP2025020227A (ja) 2015-11-03 2024-10-29 ブドウ膜炎および黄斑浮腫の処置のためのil6r抗体を含む組成物およびそれを使用する方法

Country Status (13)

Country Link
US (2) US10968278B2 (https=)
EP (1) EP3371224B1 (https=)
JP (4) JP7272794B2 (https=)
KR (2) KR20260036589A (https=)
CN (1) CN108473583A (https=)
AU (2) AU2016348418B8 (https=)
BR (1) BR112018008900A8 (https=)
CA (1) CA3003874A1 (https=)
IL (1) IL319993A (https=)
MX (2) MX2018005589A (https=)
SG (1) SG11201803654TA (https=)
TW (3) TW202339795A (https=)
WO (1) WO2017079443A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
IL319993A (en) * 2015-11-03 2025-06-01 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
AU2019329958B2 (en) 2018-08-29 2025-05-29 Regeneron Pharmaceuticals, Inc. Methods and compositions for treating subjects having rheumatoid arthritis
BR112021014377A2 (pt) 2019-01-31 2021-12-28 Regeneron Pharma Composições e métodos para o tratamento de artrite idiopática juvenil
AU2020261431A1 (en) 2019-04-24 2021-12-09 Regeneron Pharmaceuticals, Inc. Methods of diagnosis and treatment of rheumatoid arthritis
EP3980459A1 (en) 2019-06-04 2022-04-13 Sanofi Biotechnology Compositions and methods for treating pain in subj ects with rheumatoid arthritis
US20200405883A1 (en) 2019-06-20 2020-12-31 Baxalta Incorporated Method of treatment with viral-based gene therapy
CN116528892A (zh) * 2020-10-28 2023-08-01 再生生物股份有限公司 用于眼部适应症的载体化抗TNF-α抗体
AU2023369998A1 (en) * 2022-10-24 2025-01-23 F. Hoffmann-La Roche Ag Predicting response to il-6 antagonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0628639B1 (en) 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
PT783893E (pt) 1994-10-07 2012-05-24 Chugai Pharmaceutical Co Ltd Inibição do crescimento anormal das células sinoviais usando antagonistas de il-6 como componente ativo
ZA971600B (en) 1996-02-26 1997-09-22 Merck & Co Inc Treatment of macular edema.
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
CN1989439B (zh) 2004-05-06 2010-12-29 美国政府健康及人类服务部 治疗葡萄膜炎的方法以及组合物
US8080248B2 (en) * 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
WO2009140348A2 (en) * 2008-05-13 2009-11-19 Novimmune Sa Anti-il-6/il-6r antibodies and methods of use thereof
KR20130065662A (ko) 2010-05-07 2013-06-19 조마 테크놀로지 리미티드 ⅠL-1β 관련 병태의 치료 방법
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9943594B2 (en) 2011-10-11 2018-04-17 Sanofi Biotechnology Methods for the treatment of rheumatoid arthritis
BR112015010360A8 (pt) * 2012-11-08 2018-01-16 Eleven Biotherapeutics Inc antagonistas de il-6 e utilização dos mesmos.
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
AU2014352801B2 (en) 2013-11-22 2020-05-28 Regeneron Pharmaceuticals, Inc. Compositions for the treatment of rheumatoid arthritis and methods of using same
IL295414B2 (en) 2014-03-27 2026-02-01 Takeda Pharmaceuticals Co Compositions and methods for treating macular edema due to diabetes
IL319993A (en) 2015-11-03 2025-06-01 Sanofi Biotechnology Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same

Similar Documents

Publication Publication Date Title
JP2018532804A5 (https=)
Molina et al. On demand PrEP with oral TDF-FTC in the open-label phase of the ANRS IPERGAY trial
Arida et al. Anti-TNF agents for Behcet's disease: analysis of published data on 369 patients
PE20191758A1 (es) Composiciones de anticuerpo optimizadas para el tratamiento de trastornos oculares
WO2008154251A4 (en) C3b antibodies and methods for the prevention and treatment of complement- associated disorders
JP2017503820A5 (https=)
JP2015514110A5 (https=)
HRP20250022T1 (hr) Liječenje kolestatskog pruritusa sa seladelparom
JP2012165745A5 (https=)
JP2016063812A5 (https=)
AR102592A1 (es) Anticuerpos biespecíficos y métodos de uso en oftalmología
JP2018507220A5 (https=)
AR066660A1 (es) Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
Calonge Classification of ocular atopic/allergic disorders and conditions: an unsolved problem
AR102593A1 (es) Anticuerpos anti-pdgf-b y métodos de uso
JP2017502023A5 (https=)
FI3600415T3 (fi) Aktiviinireseptorin tyypin ii reseptorin vastainen vasta-aine käytettäväksi sydämen vajaatoiminnan hoidossa
WO2017079443A8 (en) Compositions comprising il6r antibodies for the treatment of uveitis and macular edema and methods of using same
JP2018530574A5 (https=)
JP2017520562A5 (https=)
AR069233A1 (es) Anticuerpos anti- factor b y sus usos
ZA201907371B (en) Methods and compositions for treating allergic ocular diseases
CN111526878A (zh) 含三萜类化合物的药物组合物及其用途
Brown et al. Boston keratoprosthesis type 1 for herpes simplex and herpes zoster keratopathy
Donoso et al. Comparative study of keratoconus between Anwar's deep anterior lamellar keratoplasty versus converted penetrating keratoplasty